OABI

OmniAb, Inc. (OABI) - 10-Q Summary for Period Ended September 30, 2025

Business Context and Reporting Period

This filing covers the quarterly period ended September 30, 2025. OmniAb, Inc. is a biotechnology company that licenses discovery research technology to pharmaceutical and biotech industries. The company utilizes a proprietary platform called "Biological Intelligence" to create optimized antibody candidates. As of the reporting date, the company had 104 active partners and 399 active programs, including 28 antibodies in clinical development and three approved products.

Key Financial Metrics

Note: Revenue is derived from license fees, milestones, service revenue, and royalties. The company reported a new revenue stream, "xPloration revenue," of $0.74 million for Q3 2025.

Material Changes vs. Prior Period

• Revenue Decline: Total revenue decreased 46% in Q3 2025 compared to Q3 2024, driven by a 55% drop in license and milestone revenue and a 52% drop in service revenue. Service revenue declined due to the completion of certain small molecule ion channel programs.
• Expense Reduction: Research and development (R&D) expenses decreased 22% to $10.38 million, and General and Administrative (G&A) expenses decreased 4% to $6.78 million. These reductions were primarily due to lower personnel costs (including reduced share-based compensation) and lower external expenses.
• Asset Sale: The company recorded a $3.0 million gain from the sale of an ion channel asset (Kv7.2 program) to Angelini Pharma in May 2025, which contributed to "Other operating income, net."
• Capital Raise: In August 2025, the company completed a private placement (PIPE) of approximately 21.25 million shares, raising gross proceeds of approximately $30.0 million.

Outlook, Risks, and Management Commentary

• Liquidity: Management believes existing cash, cash equivalents, and short-term investments ($59.5 million) are sufficient to support operations for at least the next 12 months.
• Capital Resources: The company maintains an "At-The-Market" (ATM) facility with $88.3 million remaining available. Warrants are currently "out of the money" with an exercise price of $11.50.
• Risk Factors: The filing highlights risks related to government healthcare reform, specifically the "One Big Beautiful Bill Act" enacted in July 2025, which reduces Medicaid funding. Additionally, potential tariffs and drug pricing policies by the current administration pose risks to partner profitability and, consequently, OmniAb's future royalty streams.
• Contingent Liabilities: The company holds contingent liabilities of $1.24 million (Level 3 fair value), primarily related to acquisition earn-outs, which are subject to significant estimation uncertainty.

Investor Verification Checklist

• Revenue Sustainability: Verify the timeline for future milestone payments and the commercial performance of the three approved products driving royalty revenue.
• Cash Burn Rate: Confirm the projected operating cash burn rate given the 12-month liquidity runway and the impact of the recent $30 million capital raise.
• Asset Sale Proceeds: Review the terms of the Angelini Pharma asset sale to ensure the $3.0 million gain is fully realized and not subject to future clawbacks.
• Regulatory Impact: Assess the specific impact of the July 2025 Medicaid funding cuts on the company's key partners and their ability to pay future milestones or royalties.
• Warrant Exercise: Monitor the stock price relative to the $11.50 warrant exercise price to evaluate the likelihood of future dilution or cash inflow from warrant exercises.